NewAmsterdam Pharma (NAMS) Change in Acquisitions & Divestments (2025 - 2026)

NewAmsterdam Pharma (NAMS) reported Change in Acquisitions & Divestments of $51.0 million for Q1 2026, up 308.0% on a YoY basis from $12.5 million in Q1 2025, and up 0.99% sequentially from $50.5 million in Q4 2025.

NewAmsterdam Pharma (NAMS) Change in Acquisitions & Divestments (2025 - 2026) Analysis & Trends

NewAmsterdam Pharma (NAMS) has 2 years of Change in Acquisitions & Divestments data on file, last reported at $51.0 million in Q1 2026.

  • For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 308.0% year-over-year to $51.0 million; the trailing twelve-month figure through Mar 2026 stood at $160.6 million (changed N/A YoY), and the FY2025 full-year result was $122.1 million, changed N/A from the prior year.
  • Change in Acquisitions & Divestments climbed to $51.0 million in Q1 2026, from $50.5 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $51.0 million in Q1 2026 to a low of $12.5 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,921.77 Bn 66,921.49 Bn -
2 Nanobiotix 1,911.83 Bn 1,911.77 Bn -
3 Akari Therapeutics 959.56 Bn 959.56 Bn -
4 BeOne Medicines 471.57 Bn 466.77 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.01 Bn 114.76 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.09 Bn 61.34 Bn 3.31 Bn
7 Belite Bio 62.68 Bn 62.68 Bn -
8 Argenx Se 55.86 Bn 50.68 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.48 Bn 34.47 Bn 959.66 Mn
10 NewAmsterdam Pharma 3.68 Bn 3.68 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 51.00 Mn
Mar 31, 2026 51.00 Mn
Dec 31, 2025 50.50 Mn
Dec 31, 2025 50.50 Mn
Sep 30, 2025 34.40 Mn
Sep 30, 2025 34.40 Mn
Jun 30, 2025 24.66 Mn
Jun 30, 2025 24.66 Mn
Mar 31, 2025 12.50 Mn
Mar 31, 2025 12.50 Mn